[HTML][HTML] Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases

H Ha, B Debnath, N Neamati - Theranostics, 2017 - ncbi.nlm.nih.gov
The chemokine receptors CXCR1/2 and their ligand CXCL8 are essential for the activation
and trafficking of inflammatory mediators as well as tumor progression and metastasis. The …

[HTML][HTML] Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases

Y Cheng, X Ma, Y Wei, XW Wei - … et Biophysica Acta (BBA)-Reviews on …, 2019 - Elsevier
The chemokine receptor CXCR2 and its ligands are implicated in the progression of tumours
and various inflammatory diseases. Activation of the CXCLs/CXCR2 axis activates multiple …

Massively parallel digital transcriptional profiling of single cells

GXY Zheng, JM Terry, P Belgrader, P Ryvkin… - Nature …, 2017 - nature.com
Characterizing the transcriptome of individual cells is fundamental to understanding
complex biological systems. We describe a droplet-based system that enables 3′ mRNA …

Interleukin-8 in cancer pathogenesis, treatment and follow-up

C Alfaro, MF Sanmamed, ME Rodríguez-Ruiz… - Cancer treatment …, 2017 - Elsevier
Abstract Interleukin-8 (CXCL8) was originally described as a chemokine whose main
function is the attraction of a polymorphonuclear inflammatory leukocyte infiltrate acting on …

The IL-8/IL-8R axis: a double agent in tumor immune resistance

JM David, C Dominguez, DH Hamilton, C Palena - Vaccines, 2016 - mdpi.com
Interleukin-8 (IL-8, CXCL8) is a pro-inflammatory chemokine produced by various cell types
to recruit leukocytes to sites of infection or tissue injury. Acquisition of IL-8 and/or its …

Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms

DAC Fisher, JS Fowles, A Zhou, ST Oh - Frontiers in immunology, 2021 - frontiersin.org
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms
(MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling …

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - frontiersin.org
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia

DE Reyna, TP Garner, A Lopez, F Kopp… - Cancer cell, 2017 - cell.com
The BCL-2 family protein BAX is a central mediator of apoptosis. Overexpression of anti-
apoptotic BCL-2 proteins contributes to tumor development and resistance to therapy by …

[HTML][HTML] Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production

JT Weinreb, N Ghazale, K Pradhan, V Gupta, KS Potts… - Developmental cell, 2021 - cell.com
Hematopoietic stem and progenitor cells (HSPCs) arise during embryonic development and
are essential for sustaining the blood and immune systems throughout life. Tight regulation …

Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling

DAC Fisher, CA Miner, EK Engle, H Hu, TB Collins… - Leukemia, 2019 - nature.com
The distinct clinical features of myelofibrosis (MF) have been attributed in part to
dysregulated inflammatory cytokine production. Circulating cytokine levels are elevated in …